Insilico Medicine Inc. has synthesized NLRP3 inflammasome inhibitors reported to be useful for the treatment of obesity, autoimmune disease and inflammatory disorders.

Cellus Inc. has disclosed compounds acting as disintegrin and metalloproteinase with thrombospondin motifs 4 (ADAMTS4; aggrecanase-1) and 5 (ADAMTS5; aggrecanase-2) inhibitors reported to be useful for the treatment of septic arthritis, osteoarthritis, osteonecrosis, rheumatoid arthritis and tuberculosis.

Nanjing Zaiming Pharmaceutical Co. Ltd. has described Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer.

Shandong Luye Pharmaceutical Co. Ltd. has divulged tachykinin NK3 receptor antagonists reported to be useful for the treatment of attention deficit hyperactivity disorder (ADHD), depression, pain, obesity, cognitive disorders, inflammatory disorders, psychosis and urinary incontinence, among others.

Nanjing Mingde New Drug Research Co. Ltd. has designed proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a GTPase KRAS (G12D mutant)-targeting moiety via a linker for the treatment of cancer.

Scientists at Oncopia Therapeutics Inc. (dba SK Life Science Labs) and The University of Michigan have synthesized proteolysis targeting chimera (PROTAC) compounds comprising a cereblon E3 ubiquitin ligase-binding moiety coupled to a probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α) and transcription activator BRG1 (SMARCA4; BAF190A; SNF2-β)-targeting agent through a linker.

Kangbaida (Sichuan) Biotechnology Co. Ltd. has disclosed proteolysis targeting chimeras (PROTACs) comprising a cereblon (CRBN) ligand coupled to a mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1)-targeting moiety through a linker.

A TYK Medicines Inc. patent discloses tricyclic compounds acting as CDK2/cyclin E1 inhibitors reported to be useful for the treatment of cancer.

EA Pharma Co. Ltd. has prepared and tested nitrogen-including heterocycle derivatives acting as 2-amino-3-carboxymuconate-6-semialdehyde decarboxylase (ACMSD) inhibitors.

Work at Vivozon Inc. has led to the identification of dual metabotropic glutamate mGlu5 receptor antagonists and histone deacetylase 6 (HDAC6) inhibitors.